Optimal co-occurrence matrix for automatic segmentation of ultrasonic images

This paper introduces a new method of segmentation using automatic thresholding adapted to the NDT ultrasonic images . This study is based on image analysis through co-occurrence matrixes . It shows an optimization of the r and 0 parameters of the co-occurrence matrix enabling to define more acurately the border between noise and defect echoes . The segmentation is obtained by automatically taking into account a threshold derived from a determination curve calculated front the co-occurrence matrix . This curve, called Average Product of Variances Measure, is an analysis of the distribution of the matrix coefficients . The results show behaviors of the co-occurrence matrixes and of the threshold selection curves that justify perfectly the analysis performed on the characteristics of the image .Cet article présente une nouvelle méthode de segmentation par seuillage automatique, adaptée aux images obtenues en contrôle non destructif par ultrasons. Cette étude est fondée sur l'analyse d'image par matrice de co-occurrence. On présente une optimisation des paramètres r et Θ de la matrice de co-occurrence permettant de mieux définir la frontière qui sépare le bruit des échos de défauts. La segmentation s'obtient par la prise en compte automatique d'un seuil issu d'une courbe de détermination calculée à partir de la matrice de co-occurrenc

Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies

Circulating anti-p53 antibodies have been described and used as tumoural markers in patients with various cancers and strongly correlate with the p53 mutated status of the tumours. No study has yet looked at the prevalence of such antibodies in skin carcinoma patients although these tumours have been shown to be frequently p53 mutated. Most skin carcinoma can be diagnosed by examination or biopsy, but aggressive, recurrent and/or non-surgical cases' follow up would be helped by a biological marker of residual disease. We performed a prospective study looking at the prevalence of anti-p53 antibodies using an ELISA technique in a series of 105 skin carcinoma patients in comparison with a sex- and age-matched control skin carcinoma-free group (n = 130). Additionally, p53 accumulation was studied by immunohistochemistry to confirm p53 protein altered expression in a sample of tumours. Anti-p53 antibodies were detected in 2.9% of the cases, with a higher prevalence in patients suffering from the more aggressive squamous cell type (SCC) of skin carcinoma (8%) than for the more common and slowly growing basal cell carcinoma type or BCC (1.5%). p53 protein stabilization could be confirmed in 80% of tumours studied by IHC. This low level of anti-p53 antibody detection contrasts with the high rate of p53 mutations reported in these tumours. This observation shows that the anti-p53 humoral response is a complex and tissue-specific mechanism. © 2001 Cancer Research Campaign http://www.bjcancer.co

Safe lipid nanocapsule-based gel technology to target lymph nodes and combat mediastinal metastases from an orthotopic non-small-cell lung cancer model in SCID-CB17 mice

The purpose of this study is the assessment of gel technology based on a lauroyl derivative of gemcitabine encapsulated in lipid nanocapsules delivered subcutaneously or intravenously after dilution to target lymph nodes, induce less systemic toxicity and combat mediastinal metastases from an orthotopic model of human, squamous, non-small-cell lung cancer Ma44-3 cells implanted in severe combined immunodeficiency mice. The gel technology mainly targeted lymph nodes as revealed by the biodistribution study. Moreover, the gel technology induced no significant myelosuppression (platelet count) in comparison with the control saline group, unlike the conventional intravenous gemcitabine hydrochloride treated group (P < 0.05). Besides, the gel technology, delivered subcutaneously twice a week, was able to combat locally mediastinal metastases from the orthotopic lung tumor and to significantly delay death (P < 0.05) as was the diluted gel technology delivered intravenously three times a week

Protection from ultraviolet damage and photocarcinogenesis by vitamin d compounds

© Springer Nature Switzerland AG 2020. Exposure of skin cells to UV radiation results in DNA damage, which if inadequately repaired, may cause mutations. UV-induced DNA damage and reactive oxygen and nitrogen species also cause local and systemic suppression of the adaptive immune system. Together, these changes underpin the development of skin tumours. The hormone derived from vitamin D, calcitriol (1,25-dihydroxyvitamin D3) and other related compounds, working via the vitamin D receptor and at least in part through endoplasmic reticulum protein 57 (ERp57), reduce cyclobutane pyrimidine dimers and oxidative DNA damage in keratinocytes and other skin cell types after UV. Calcitriol and related compounds enhance DNA repair in keratinocytes, in part through decreased reactive oxygen species, increased p53 expression and/or activation, increased repair proteins and increased energy availability in the cell when calcitriol is present after UV exposure. There is mitochondrial damage in keratinocytes after UV. In the presence of calcitriol, but not vehicle, glycolysis is increased after UV, along with increased energy-conserving autophagy and changes consistent with enhanced mitophagy. Reduced DNA damage and reduced ROS/RNS should help reduce UV-induced immune suppression. Reduced UV immune suppression is observed after topical treatment with calcitriol and related compounds in hairless mice. These protective effects of calcitriol and related compounds presumably contribute to the observed reduction in skin tumour formation in mice after chronic exposure to UV followed by topical post-irradiation treatment with calcitriol and some, though not all, related compounds

Novel Gemcitabine Conjugated Albumin Nanoparticles: a Potential Strategy to Enhance Drug Efficacy in Pancreatic Cancer Treatment

Purpose: The present study reports a novel conjugate of gemcitabine (GEM) with bovine serum albumin (BSA) and thereof nanoparticles (GEM-BSA NPs) to potentiate the therapeutic efficacy by altering physicochemical properties, improving cellular uptake and stability of GEM. Methods: The synthesized GEM-BSA conjugate was extensively characterized by NMR, FTIR, MALDI-TOF and elemental analysis. Conjugation mediated changes in structural conformation and physicochemical properties were analysed by fluorescence, Raman and CD spectroscopy, DSC and contact angle analysis. Further, BSA nanoparticles were developed from BSA-GEM conjugate and extensively evaluated against in-vitro pancreatic cancer cell lines to explore cellular uptake pathways and therapeutic efficacy. Results: Various characterization techniques confirmed covalent conjugation of GEM with BSA. GEM-BSA conjugate was then transformed into NPs via high pressure homogenization technique with particle size 147.2 ± 7.3, PDI 0.16 ± 0.06 and ZP -19.2 ± 1.4. The morphological analysis by SEM and AFM revealed the formation of smooth surface spherical nanoparticles. Cellular uptake studies in MIA PaCa-2 (GEM sensitive) and PANC-1 (GEM resistant) pancreatic cell lines confirmed energy dependent clathrin internalization/endocytosis as a primary mechanism of NPs uptake. In-vitro cytotoxicity studies confirmed the hNTs independent transport of GEM in MIA PaCa-2 and PANC-1 cells. Moreover, DNA damage and annexin-V assay revealed significantly higher apoptosis level in case of cells treated with GEM-BSA NPs as compared to free GEM. Conclusions: GEM-BSA NPs were found to potentiate the therapeutic efficacy by altering physicochemical properties, improving cellular uptake and stability of GEM and thus demonstrated promising therapeutic potential over free drug

The VINON-LOCA test facility: exploring the LOCA phenomenology through an out-of-pile thermal sequence on irradiated pressurized fuel rod

Since the out-of-pile semi-integral tests performed at Studsvik in 2011 for the NRC [1] and the Halden Loss-Of-Coolant Accident (LOCA) test series IFA-650 [2], a major safety interest has raised for Fuel Fragmentation, Relocation and Dispersal (FFRD) during a LOCA sequence. In addition to the characteristics of the fuel ejected from the rod after the clad failure, the fuel behaviour before the clad failure is still to be investigated, especially its fragmentation and its possible relocation within the rod during the clad ballooning phase. Furthermore, the chronology and the sequencing of these phenomena is of particular interest. For this purpose, the VINON-LOCA program, lying in the framework of a trilateral agreement between EDF, Framatome and CEA, is aimed at performing Out-Of-Pile heating tests on irradiated repressurized fuel rods, reproducing a typical Loss Of Coolant Accident thermal sequence. The VINON-LOCA experimental set-up is located in the so-called VERDON lab of the LECA-STAR hot cell complex. This lab was dedicated to the VERDON-ISTP program [3]. The VINON-LOCA set-up is thus largely instrumented for addressing not only these FFRD topics, but also Fission Gas Release (FGR), combining both online measurement (gamma stations, gamma camera, acoustic sensor, pressure, temperatures, flow meters, microGC…), and preand post-test characterization (gamma scanning, tomography, metrology, fuel fragments weighing and sieving, gas analyses…). An extensive and substantial qualification campaign has been performed to validate the furnace design regarding the desired test conditions, and to qualify the instrumentation. Following some preliminary modelling and calculations, it has included tests on an out-of-cell twin mockup and tests on dummy inactive rods in the hot cell. This allowed achieving successfully the first experimental qualification test of the program end of 2019 on an irradiated UO2 fuel rodlet. A second irradiated experiment is planned with increased instrumentation capabilities, notably a 2D gamma camera for online fuel motion detection